A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function in Infants and Young Children (BEGIN Study)
Latest Information Update: 14 Aug 2024
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary) ; Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- Acronyms BEGIN
- 12 Aug 2024 Planned End Date changed from 1 Oct 2025 to 1 Dec 2029.
- 12 Aug 2024 Planned primary completion date changed from 1 Oct 2025 to 1 Dec 2029.
- 04 May 2023 Status changed from active, no longer recruiting to recruiting.